Fibromyalgia Treatment Market By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The fibromyalgia treatment market is likely to experience a significant growth rate of 4.0% from 2023-2032 owing to increasing market demand from pharmaceutical sector - Allied Market Research

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and tenderness in various parts of the body. It is considered as a complex condition because its exact cause is not well understood, and there is no definitive diagnostic test for fibromyalgia. The primary symptom of fibromyalgia is chronic pain that affects body parts such as muscles, joints, and soft tissues. The pain may be described as a dull ache, a burning sensation, or a deep muscular soreness. It is often accompanied by other symptoms such as fatigue, sleep disturbances, cognitive difficulties, mood disorders, and heightened sensitivity to touch. People with fibromyalgia may experience pain more intensely or feel pain in response to stimuli that would not typically cause pain or discomfort in others.

It involves a complex interaction between the central nervous system, neurotransmitters, and the way pain signals are processed in the brain. Diagnosing fibromyalgia can be challenging as there are no specific laboratory tests or imaging studies that can definitively confirm the condition. Treatment for fibromyalgia focuses on managing symptoms and improving quality of life by using medications to alleviate the symptoms along with improving sleep and maintaining a healthy diet and exercise.

The growth of the global fibromyalgia treatment market is majorly driven by alarming rise in prevalence of fibromyalgia. According to the National Fibromyalgia Association (2023), fibromyalgia affects an estimated 10 million people in the U.S. and is mostly seen among women, with a prevalence of 75-90%. Moreover, fibromyalgia is more commonly diagnosed in middle-aged and older individuals. As the global population continues to age, the number of people at risk for developing fibromyalgia increases, leading to a larger patient pool requiring treatment. Thus, rise in prevalence of fibromyalgia boosts the demand for effective treatment medications, which, in turn, propels the growth of the market.

In addition, surge in awareness regarding fibromyalgia and its diagnosis and treatment among the people in developed countries acts as a major driver of the global market. Improved diagnosis and awareness have played a significant role in the identification and treatment of fibromyalgia. In the past, fibromyalgia was often misunderstood or misdiagnosed, leading to delayed or ineffective treatment for many individuals.

Moreover, in past few years, healthcare professionals and the general population have increasingly acknowledged and gained a better understanding of fibromyalgia condition. For instance, diagnostic criteria for fibromyalgia have evolved and become more refined. The American College of Rheumatology (ACR) has established updated diagnostic criteria, along with other assessment tools, which have helped healthcare professionals more accurately diagnose fibromyalgia. This will further significantly contribute to the growth of the fibromyalgia treatment market.

However, in addition to conventional medical approaches, certain individuals with fibromyalgia may explore alternative treatment options to help manage their symptoms. For instance, acupuncture and other therapies may be involved which hinder the market growth to some extent.

In addition, lack of knowledge and awareness about fibromyalgia in underdeveloped countries may have a negative impact on the growth of the market. In underdeveloped countries, there may be limited healthcare infrastructure, fewer trained healthcare professionals, and lack of specialized clinics or resources dedicated to chronic pain conditions such as fibromyalgia. This contribute to lack of awareness among both healthcare providers and the general population, which acts as a key deterrent factor of the global market.

On the contrary, a robust pipeline of products for fibromyalgia treatment presents an encouraging outlook for both patients and key players in the market. The development of new medications specifically targeting fibromyalgia holds the potential to address the unmet needs of patients and improve their quality of life. Continuous research and development efforts by pharmaceutical companies, researchers, and healthcare professionals demonstrate a commitment to finding more effective and safer treatment options for fibromyalgia. This includes exploring novel therapeutic approaches and investigating potential targeted therapies. Such strategies adopted by key players are anticipated to boost market growth during the forecast period.

In addition, emerging countries in Asia-Pacific and LAMEA present lucrative opportunities for key players looking to invest in the fibromyalgia treatment market. This is attributed to the fact that these regions are characterized by the presence of a large population base with notable economic growth and increase in healthcare expenditure. In addition, an alarming rise in prevalence of fibromyalgia in these regions along with rise in awareness about the condition is anticipated to drive the market growth.

The global fibromyalgia treatment market is segmented into drug class, distribution channel, and region. Depending on drug class, the market is categorized into antidepressants, anticonvulsants, muscle relaxants, and others. Based on distribution channel, it is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players that operate in the market include Abbott Laboratories Abbvie Inc., Amneal Pharmaceuticals LLC, Eli Lilly and Company, Lupin, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Viatris Inc., and Zydus Lifesciences Limited.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fibromyalgia treatment market analysis from 2022 to 2032 to identify the prevailing fibromyalgia treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the fibromyalgia treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global fibromyalgia treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Antidepressants
Anticonvulsants
Muscle Relaxants
Others

By Distribution Channel

Hospital pharmacies
Drug stores and retail pharmacies
Online providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
AbbVie Inc.
Amneal Pharmaceuticals LLC
Zydus Lifesciences Limited
Sun Pharmaceutical Industries Limited
Eli Lilly and Company
Novartis AG
Viatris Inc.
Lupin Limited.

Product Code: A13357

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Significant prevalence of fibromyalgia among the population
  - 3.4.1.2. Surge in awareness regarding fibromyalgia and its treatment
  - 3.4.1.3. Enhanced access to generic medications for fibromyalgia treatment

3.4.2. Restraints
- 3.4.2.1. Availability of alternate treatment options
- 3.4.2.2. Lack of awareness about fibromyalgia in underdeveloped countries

3.4.3. Opportunities
- 3.4.3.1. Robust pipeline of products for fibromyalgia treatment

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Antidepressants
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Anticonvulsants
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Muscle Relaxants
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country

CHAPTER 5: FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Hospital pharmacies
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drug stores and retail pharmacies
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Online providers
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: FIBROMYALGIA TREATMENT MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Drug Class
- 6.2.3. Market size and forecast, by Distribution Channel
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Key market trends, growth factors and opportunities
  - 6.2.4.1.2. Market size and forecast, by Drug Class
  - 6.2.4.1.3. Market size and forecast, by Distribution Channel
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Key market trends, growth factors and opportunities
  - 6.2.4.2.2. Market size and forecast, by Drug Class
  - 6.2.4.2.3. Market size and forecast, by Distribution Channel
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Key market trends, growth factors and opportunities
  - 6.2.4.3.2. Market size and forecast, by Drug Class
  - 6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Drug Class
- 6.3.3. Market size and forecast, by Distribution Channel
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Key market trends, growth factors and opportunities
  - 6.3.4.1.2. Market size and forecast, by Drug Class
  - 6.3.4.1.3. Market size and forecast, by Distribution Channel
  - 6.3.4.2. France
  - 6.3.4.2.1. Key market trends, growth factors and opportunities
  - 6.3.4.2.2. Market size and forecast, by Drug Class
  - 6.3.4.2.3. Market size and forecast, by Distribution Channel
  - 6.3.4.3. UK
  - 6.3.4.3.1. Key market trends, growth factors and opportunities
  - 6.3.4.3.2. Market size and forecast, by Drug Class
  - 6.3.4.3.3. Market size and forecast, by Distribution Channel
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Key market trends, growth factors and opportunities
  - 6.3.4.4.2. Market size and forecast, by Drug Class
  - 6.3.4.4.3. Market size and forecast, by Distribution Channel
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Key market trends, growth factors and opportunities
  - 6.3.4.5.2. Market size and forecast, by Drug Class
  - 6.3.4.5.3. Market size and forecast, by Distribution Channel
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Key market trends, growth factors and opportunities
  - 6.3.4.6.2. Market size and forecast, by Drug Class
  - 6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Drug Class
- 6.4.3. Market size and forecast, by Distribution Channel
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Key market trends, growth factors and opportunities
  - 6.4.4.1.2. Market size and forecast, by Drug Class
  - 6.4.4.1.3. Market size and forecast, by Distribution Channel
  - 6.4.4.2. China
  - 6.4.4.2.1. Key market trends, growth factors and opportunities
  - 6.4.4.2.2. Market size and forecast, by Drug Class
  - 6.4.4.2.3. Market size and forecast, by Distribution Channel
  - 6.4.4.3. India
  - 6.4.4.3.1. Key market trends, growth factors and opportunities
  - 6.4.4.3.2. Market size and forecast, by Drug Class
  - 6.4.4.3.3. Market size and forecast, by Distribution Channel
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Key market trends, growth factors and opportunities
  - 6.4.4.4.2. Market size and forecast, by Drug Class
  - 6.4.4.4.3. Market size and forecast, by Distribution Channel
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Key market trends, growth factors and opportunities
  - 6.4.4.5.2. Market size and forecast, by Drug Class
  - 6.4.4.5.3. Market size and forecast, by Distribution Channel
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Key market trends, growth factors and opportunities
  - 6.4.4.6.2. Market size and forecast, by Drug Class
  - 6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Drug Class
- 6.5.3. Market size and forecast, by Distribution Channel
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Key market trends, growth factors and opportunities
  - 6.5.4.1.2. Market size and forecast, by Drug Class
  - 6.5.4.1.3. Market size and forecast, by Distribution Channel
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Key market trends, growth factors and opportunities
  - 6.5.4.2.2. Market size and forecast, by Drug Class
  - 6.5.4.2.3. Market size and forecast, by Distribution Channel
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Key market trends, growth factors and opportunities
  - 6.5.4.3.2. Market size and forecast, by Drug Class
  - 6.5.4.3.3. Market size and forecast, by Distribution Channel
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Key market trends, growth factors and opportunities
  - 6.5.4.4.2. Market size and forecast, by Drug Class
  - 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Abbott Laboratories
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. Amneal Pharmaceuticals LLC
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. Eli Lilly and Company
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Lupin Limited.
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. Novartis AG
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Viatris Inc.
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
8.7. Zydus Lifesciences Limited
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
- 8.7.7. Key strategic moves and developments
8.8. Sun Pharmaceutical Industries Limited
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Teva Pharmaceutical Industries Ltd.
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. AbbVie Inc.
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance
- 8.10.7. Key strategic moves and developments